Unlocking the potential of microRNA as predictive biomarkers for efficacy and adverse events in immune checkpoint inhibitor therapy (Review)
Immune checkpoint inhibitors (ICIs) have shown promise in cancer therapy by enhancing antitumor immune responses, but patient responses are variable, with some experiencing limited efficacy and others suffering from severe immune-related adverse events (irAEs). Identifying predictive biomarkers for ICI efficacy and tox...